

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 2

PATENT
Attorney Docket No. SALK1520-2

OFFICIAL

In The Claims:

Please cancel claim 25 to 34 and 43 to 46 without prejudice, and amend claims 1, 11, 12 and 20 to 24 as follows:

1. (Amended) A method for modulating the expression of an exogenous gene in a mammalian subject cell containing:
 - (i) a DNA construct comprising said exogenous gene under the control of an ecdysone response element; and
 - (ii) a modified ecdysone receptor which, in the presence of a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element;
said method comprising administering to said subject providing to the cell an effective amount of a ligand for said modified ecdysone receptor; wherein said ligand is not normally present in the cells of said subject cell; and wherein said ligand is not toxic to said subject cell.
11. (Amended) A method according to claim 11 47 wherein said receptor capable of acting as a silent partner is RXR.
12. (Amended) A method according to claim 11 wherein said RXR is exogenous to said mammalian subject cell.
20. (Amended) A method according to claim 19 wherein said wild type gene is selected from genes which encode products:
the substantial absence of which leads to the occurrence of a non-normal state in said subject cell; or
a substantial excess of which leads to the occurrence of a non-normal state in said subject cell.

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 3

PATENT
Attorney Docket No. SALK1520-2

21. (Amended) A method according to claim 19 wherein said therapeutic gene is selected from those which encode products:

which are toxic to the cells in which they are expressed; or
which impart a beneficial property to said subject cells.

22. (Amended) A method of inducing the expression of an exogenous gene in a mammalian subject cell containing:

- (i) a DNA construct comprising an exogenous gene under the control of an ecdysone response element,
- (ii) DNA encoding a modified ecdysone receptor under the control of an inducible promoter; wherein said modified ecdysone receptor, in the presence of a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element, and
- (iii) a ligand for said modified ecdysone receptor;
said method comprising subjecting said subject cell to conditions suitable to induce expression of said modified ecdysone receptor.

23. (Amended) A method of inducing expression of an exogenous gene in a mammalian subject cell containing a DNA construct containing said exogenous gene under the control of an ecdysone response element, said method comprising introducing into said subject cell:

- a modified ecdysone receptor, and
- a ligand for said modified ecdysone receptor,
wherein said receptor, in combination with a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element, activating transcription therefrom.

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 4

PATENT
Attorney Docket No. SALK1520-2

24. (Amended) A method for the expression of a recombinant product detrimental to [a host organism] host cells, said method comprising:

transforming suitable host cells with:

(i) a DNA construct encoding said recombinant product under the control of an ecdysone response element, and

(ii) DNA encoding a modified ecdysone receptor;

growing said host cells in suitable media; and

inducing expression of said recombinant product by introducing into said host cells ligand(s) for said modified ecdysone receptor, and optionally a receptor capable of acting as a silent partner for said modified ecdysone receptor.

Please add new claims 47 to 56 as follows:

47. (New) A method according to claim 1, wherein said receptor capable of acting as a silent partner is present.

48. (New) A method according to claim 47 wherein said receptor capable of acting as a silent partner is ultraspiracle.

49. (New) A method according to claim 1 wherein said modified ecdysone receptor has substantially no binding affinity for endogenous response elements.

GT\6214699.2
62574-991522

In Re Application of:
Evans et al.
Filed: March 16, 1998
Application No.: 09/042,488
Page 5

PATENT
Attorney Docket No. SALK1520-2

50. (New) A method for modulating the expression of an exogenous gene in a cell containing:
(i) a DNA construct comprising said exogenous gene under the control of an ecdysone response element; and
(ii) a modified ecdysone receptor which, in the presence of a ligand therefor, and in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element;
said method comprising providing to said cell an effective amount of a ligand for said modified ecdysone receptor; wherein said ligand is not normally present in said cell; and wherein said ligand is not toxic to said cell.

51. (New) A method according to claim 52, wherein said receptor capable of acting as a silent partner is RXR.

52. (New) A method according to claim 52, wherein said receptor capable of acting as a silent partner is ultraspiracle.

53. (New) A method for modulating the expression of an exogenous gene in a mammalian cell containing:
(i) a DNA construct comprising said exogenous gene under the control of an ecdysone response element; and
(ii) a modified ecdysone receptor which, in the presence of a ligand therefor, and optionally in the further presence of a receptor capable of acting as a silent partner therefor, binds to said ecdysone response element;
said method comprising providing to said mammalian cell an effective amount of a ligand for said modified ecdysone receptor; wherein said ligand is not normally present in said mammalian cell; and wherein said ligand is not toxic to said mammalian cell.

54. (New) A method according to claim 1, wherein said receptor capable of acting as a silent partner is present.

GT6214699.2
62574-991522